Natixis Advisors
CYTK icon

Natixis Advisors’s Cytokinetics CYTK Stock Holding History

Natixis Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.54M Buy
53,358
+19,642
+58% +$1.41M 0.01% 936
2026
Q1 		$2.22M Buy
33,716
+7,466
+28% +$475K ﹤0.01% 1081
2025
Q4 		$1.67M Buy
26,250
+3,688
+16% +$229K ﹤0.01% 1106
2025
Q3 		$1.24M Buy
22,562
+4,089
+22% +$168K ﹤0.01% 1244
2025
Q2 		$610K Sell
18,473
-26,992
-59% -$939K ﹤0.01% 1428
2025
Q1 		$1.83M Buy
45,465
+11,806
+35% +$543K ﹤0.01% 1108
2024
Q4 		$1.58M Sell
33,659
-3,936
-10% -$204K ﹤0.01% 1172
2024
Q3 		$1.99M Sell
37,595
-9,846
-21% -$549K ﹤0.01% 1089
2024
Q2 		$2.57M Sell
47,441
-3,035
-6% -$183K 0.01% 968
2024
Q1 		$3.54M Sell
50,476
-12,486
-20% -$966K 0.01% 886
2023
Q4 		$5.26M Buy
62,962
+19,124
+44% +$693K 0.01% 734
2023
Q3 		$1.29M Sell
43,838
-4,665
-10% -$155K ﹤0.01% 1109
2023
Q2 		$1.58M Buy
48,503
+8,652
+22% +$320K ﹤0.01% 1036
2023
Q1 		$1.4M Buy
39,851
+6,104
+18% +$249K ﹤0.01% 1048
2022
Q4 		$1.55M Sell
33,747
-2,458
-7% -$106K 0.01% 1020
2022
Q3 		$1.75M Buy
36,205
+1,216
+3% +$58.5K 0.01% 931
2022
Q2 		$1.38M Buy
34,989
+12,641
+57% +$509K 0.01% 1019
2022
Q1 		$823K Sell
22,348
-338
-1% -$12K ﹤0.01% 1174
2021
Q4 		$1.03M Buy
22,686
+2,970
+15% +$115K ﹤0.01% 1118
2021
Q3 		$705K Buy
19,716
+2,577
+15% +$75.9K ﹤0.01% 1153
2021
Q2 		$339K Sell
17,139
-772
-4% -$18.1K ﹤0.01% 1265
2021
Q1 		$416K Sell
17,911
-971
-5% -$20.7K ﹤0.01% 1191
2020
Q4 		$392K Buy
+18,882
New +$345K ﹤0.01% 1151

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's CYTK Position: Q2 2026 in Review

Natixis Advisors increased its Cytokinetics (CYTK) stake by 58% in Q2 2026, buying an estimated $1.41M and bringing the position to 53,358 shares worth $4.54M. The position accounts for 0.01% of the portfolio, ranked #936.

Natixis Advisors first reported a position in CYTK in Q4 2020 and has held it in 23 quarters since. The position peaked at $5.26M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Natixis Advisors held 53,358 shares of Cytokinetics worth $4.54M as of Q2 2026.
  • Natixis Advisors bought 19,642 Cytokinetics shares in Q2 2026, an estimated $1.41M.
  • Cytokinetics made up 0.01% of Natixis Advisors's portfolio in Q2 2026, its #936 holding.
  • Natixis Advisors first reported a position in Cytokinetics in Q4 2020 and has held it in 23 quarters since.
  • Natixis Advisors's Cytokinetics position peaked at $5.26M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.